Climb Bio Stock Analysis

Climb Stock Analysis Notes

About 85.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Climb Bio recorded a loss per share of 1.78. The entity had not issued any dividends in recent years. For more info on Climb Bio please contact BAO BCh at 866 857 2596 or go to https://climbbio.com.

Climb Bio Investment Alerts

Climb Largest EPS Surprises

View All Earnings Estimates

Climb Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.82 M.

Climb Profitablity

Management Efficiency

Climb Bio has return on total asset (ROA) of (0.1895) % which means that it has lost $0.1895 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6204) %, meaning that it created substantial loss on money invested by shareholders. Climb Bio's management efficiency ratios could be used to measure how well Climb Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of July 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Climb Bio's Non Current Assets Total are very stable compared to the past year. As of the 22nd of July 2025, Non Currrent Assets Other is likely to grow to about 423.1 K, while Other Current Assets are likely to drop about 2.7 M.

Technical Drivers

As of the 22nd of July, Climb Bio shows the Downside Deviation of 4.04, mean deviation of 3.34, and Risk Adjusted Performance of 0.0391. Climb Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Climb Bio information ratio, as well as the relationship between the potential upside and kurtosis to decide if Climb Bio is priced correctly, providing market reflects its regular price of 1.41 per share. Please also double-check Climb Bio total risk alpha, which is currently at (0.49) to validate the company can sustain itself at a future point.

Climb Bio Price Movement Analysis

Climb Bio Insider Trading Activities

Climb Bio Outstanding Bonds

Climb Bio Predictive Daily Indicators

Climb Bio Forecast Models

Climb Bio's time-series forecasting models are one of many Climb Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Climb Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Climb Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Climb shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Climb Bio. By using and applying Climb Stock analysis, traders can create a robust methodology for identifying Climb entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Climb analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Climb analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Climb Bio stock analysis indicators help investors evaluate how Climb Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Climb Bio shares will generate the highest return on investment. By understating and applying Climb Bio stock analysis, traders can identify Climb Bio position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.